[Infographics] STRIDE vs atezolizumab + bevacizumab in 1L HCC – is there any difference in OS

Focusing on dual immunotherapy in unresectable HCC:

• STRIDE (single tremelimumab regular interval durvalumab) is the first and only IO regimen to date with 6-year OS data in unresectable HCC.¹

• In the HIMALAYA study, STRIDE was compared vs sorafenib and achieved a 1.9 times higher 6-year OS rate.¹

• Real-world data indicate that there are no significant differences between STRIDE and atezolizumab + bevacizumab as 1L therapies for advanced HCC, showing them to be equally valid options for patients with advanced HCC.²

Related MIMS Drugs

IMFINZI

IMJUDO

Resources

[Infographics] STRIDE vs atezolizumab + bevacizumab in 1L HCC – is there any difference in OS

Open PDF

[Infographics] STRIDE vs atezolizumab + bevacizumab in 1L HCC – is there any difference in OS

Open PDF